Session's 'Rational' Marijuana Could be Positive for Leading Key Pot States

Thursday, December 7, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

USA News Group News Commentary

LOS ANGELES, December 7, 2017 /PRNewswire/ --


News Group - While several states made the decision to vote in favor of cannabis legalization last year, the feds lead by the Attorney General are still wrestling with the legal terms. In a positive step, AG Jeff Sessions released a statement that
the DOJ is looking at what he called a 'rational policy' toward marijuana.

This news sent positive signals to the legal cannabis industry, which is already seeing huge demand as states move into various legalization phases in 2018 led by California.

Companies impacted in the grower and producer category include Aphria (TSX: APH) (OTCQB: APHQF), Cannabics Pharmaceuticals Inc. (OTC: CNBX), AmeriCann, Inc. (OTC: ACAN) and MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF).

Based on the softening attitudes towards legalization and growth in demand, marijuana stocks have been trending higher over the entire year. Data shows that of the dozen largest pot stocks by market cap, the average marijuana stock is up well in excess of 100% - some Canadian based companies even more.

Leaders in the producer group include Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), Aphria (TSX: APH) (OTC: APHQF) and AmeriCann, Inc (OTCQB: ACAN). These companies are already licensed legal growers of cannabis and are rapidly expanding their growing capacity to accommodate demands from new markets.

Several of the cannabis Licensed Producers (or LPs) are in the grower end of the business and combining their efforts with product development, sales and distribution. MYM Nutraceuticals Inc. (CSE: MYM) (OTC: MYMMF), is a unique example of a developer of three sizeable growing operations that is broadly diversified into multi-brand development and product distribution.

California is preparing for legal sales of recreational marijuana to begin on January 1, 2018.

Nevada followed Oregon's model, allowing medical marijuana dispensaries to sell to adults 21 and older while they prepare by licensing and regulating new cannabis businesses. Authorities in California, Maine and Massachusetts all decided to wait until 2018 to begin sales of recreational pot.


Attorney General Jeff Sessions said last week that the Justice Department is examining ways to work toward a 'rational' marijuana policy. He did not provide details, such as whether the DOJ will crack down on states where the drug has been legalized.

"We're looking very hard on that right now. In fact, we had meetings yesterday and talked about it at some length," Sessions said about the department's stance toward marijuana during an announcement on new funding and tools to combat the opioid crisis. He did not provide further details.

The attorney general says that he views pot as 'detrimental' and noted that consumption is still a federal violation.

"I don't want to suggest in any way that this department in any way believes that marijuana is harmless, people should avoid it," he said.

However, this new language by Sessions signals a softer, more reasonable approach to the larger issue.

Sessions holds the power over the federal enforcement arm of criminal laws, such as the Controlled Substances Act.

The marijuana industry is governed by a legal memorandum issued by the Justice Department in 2013 that adopted a policy of non-interference with marijuana-friendly state laws, so long as they don't threaten other federal priorities. That would include things like preventing the distribution of the drug to minors, supporting cartels or other illegal activities.

That memorandum is open to modification by the Justice Department under Sessions.


Much like Canada, which has been a front runner in the push to legalize marijuana, California is poised to be the first state to have a fully functional legal recreational cannabis market open for business. This puts California right in the crosshairs.

The state is clearly getting ready; the Bureau of Cannabis Control put their proposed regulations up for review in September in Long Beach, Fresno, and Sacramento.

All this is pushing up the numbers for cannabis.

Cannabis sales are expected to reach $3.8 billion in 2018, and up to $6.6 billion by 2025, according to projections from New Frontier Data.

Based on these numbers, this could increase nationwide sales of the plant to $24.1 billion by 2025 - a number is going to continue to grow as more states enter the legal cannabis market in the coming years.

The X factor in this mix is Canada, which is expected legalize recreational use in mid-2018. The added demand for weed there is creating a real boom -one that could easily create a shortfall in as little as a year from now.

It's important to note that Medical marijuana has been legal in Canada since 2001. According to their national health agency, the number of eligible registered medical patients is increasing by about 10% a month. 

The rapid growth in medical-cannabis customers and the now forecast legalization demand has cannabis producers in that country working to expand their production capacity at a breakneck pace.


A perfect example of the efforts to increase supplies is MYM Nutraceuticals - a junior company quickly vaulting itself up the ranks of the major legal producers in Canada.

MYM Nutraceuticals is moving full speed on three planned facilities; a grow operation in Laval, Quebec to be completed this year, a joint-venture for a 1 million square foot facility in Casino, Australia and the flagship facility; a 1.5 million square foot greenhouse facility in Weedon, Quebec.

Weedon will be a massive marijuana operation -one of the largest grow operations on the planet. It will house the potential to produce over 150,000 kg of cannabis per year worth a staggering $750 million.

MYM Nutraceuticals is also diversifying; besides growing and cultivation at Laval, Casino and Weedon, MYM is advancing formulation and production to support branding and distribution of its entities Joshua Tree, MyHemp Skin Therapy, and HempMed offerings.

These subsidiaries develop and sell a variety of cannabis based natural products including custom-made cannabis products with tailored CBD chemistries along with tinctures, concentrates and oils, edibles, vape products and pet care products.

As the industry matures and seeks more sophisticated solutions from leading suppliers, this model is likely to become more common in states like California too.


Since California already has the oldest and most profitable medical marijuana market in the country, it's likely that they will have one of the most successful recreational markets as well.

California lawmakers have been working diligently to stick to a one-year plan to get the new market up and running, while Massachusetts and Maine have to pause until later in 2018.

If, as the numbers suggest, the industry will experience an aggregate of 300% growth in legal U.S. sales between 2016 and 2021, Cannabis sales will easily reach the expected $17 billion mark.

Those are some massive numbers that put pressure on legislators to 'do the right thing'.

And while Canadian cannabis companies may have set the standard for sales growth and early profits, California's model is about to test the boundaries with a need for much greater supplies.

If legalized on time as envisioned, and taken with a 'rational' approach, companies in the production, product development and distribution and their investors now could be the biggest benefactors of this new national attitude.


Cannabics Pharmaceuticals Inc. (OTCQB: CNBX)

Cannabics Pharmaceuticals announced recently that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids. The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis. Our forward looking plan encompasses a synergy between HTS (High Throughput Screening), CTCs (Circulating Tumor Cells), Drug Efficacy, and Genomic Data to provide therapists and their patients with personalized supportive data for their treatment. 


Aphria Inc., boasts itself as one of Canada's lowest cost producers, that produces, supplies and sells medical cannabis. Located in the greenhouse capital of Canada, Leamington, Ontario, Aphria provides pharma-grade medical cannabis, and quality patient care. Aphria was the first public LP to report positive cash flow from operations, and the first to report positive earnings in consecutive quarters.

AmeriCann, Inc. (OTCQB: ACAN)

AmeriCann, Inc. develops, owns and supports advanced medical cannabis cultivation and processing facilities nationwide. The Company has a multi-market portfolio of over 1,000,000 square feet of sustainable cannabis production infrastructure in various stages of development. To support local businesses that seek to serve cannabis patients in their communities the company initiated the AmeriCann Preferred Partner Program. Through this program they provide an essential set of resources including advance cultivation facilities, access to a team of experts and in certain cases, capital for our partner's businesses. In addition, AmeriCann's team has been instrumental in winning cannabis licenses in competitive application processes throughout the country.

For a more in-depth look into MYM you can view the in-depth report at USA News Group:

Article Source:

Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of USA News Group only and are subject to change without notice.USA News Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.

DISCLAIMER: USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Media Contact Information: FN Media Group, LLC e-mail: U.S. Phone: +1(954)345-0611


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store